

## Original article

# Efficacy of olibanum and propolis medicinal extracts versus metronidazole in *Giardia lamblia* experimentally infected mice

Asmaa Mohamed Farouk Al-Ghandour <sup>\*1</sup>, Hytham Kamal Ahmed <sup>2</sup>, Amal Salem <sup>3</sup>, Al-Sayed Mohammed Tealeb <sup>4</sup>, Rasha Mohamed Sabry Mohamed <sup>3</sup>, Asmaa Mohammed Yousef <sup>1</sup>

1- Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Egypt.

2- Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt.

3- Department of Clinical Pharmacology, Faculty of Medicine, Zagazig University, Egypt.

4- Department of pathology, Faculty of Medicine, Zagazig University, Egypt

## ARTICLE INFO

### Article history:

Received 20 October 2020

Received in revised form 24 October 2020

Accepted 24 October 2020

### Keywords:

*G. lamblia*

Olibanum

Propolis

Histopathology

Immunochromatography.

## ABSTRACT

**Background:** Giardiasis is a common intestinal infection, recently included by the World Health Organization in the 'Neglected Diseases Initiative'. Despite the efficacy of nitroimidazoles; the main anti-giardial chemotherapeutics, adverse effects and resistance enforced developing non-chemical alternatives. The present study aimed to assess the therapeutic efficacy of ethanol extract of olibanum (OL), propolis (PR), and their combination versus metronidazole (MTZ) against *Giardia lamblia* (*G. lamblia*) infection.

**Methods:** Sixty Swiss male albino mice were randomly divided into 6 groups; 10 mice each, Group I: normal control (non-treated; non-infected). Group II: infected with *G. lamblia* cysts, non-treated. On the 8<sup>th</sup> day post infection (dPI), the remaining 4 infected groups were treated orally with: Group III: (OL). Group IV: (PR). Group V: combination of (OL+PR). Group VI: (MTZ). These mice were subjected to direct parasitological diagnosis of *Giardia* trophozoite in intestinal exudate, immunochromatographic test for antigen detection and histopathological studies. **Results:** After 7 days therapy, complete clearance of *Giardia* trophozoites were in the combination of (OL+PR) and MTZ groups therapy. Lower percentages of reduction (91%) & (83%) were recorded in PR and OL-treated groups, respectively. Histopathological examination showed marked healing of intestinal mucosa using non-chemical combination and different degrees of dysplasia using MTZ, while partial healing was observed using olibanum and propolis separately. **Conclusion:** Olibanum, PR and their combination were proved to enhance the clearance of *Giardia* trophozoites; with progressive improvement of the histopathological changes of jejunal mucosa, making good non-chemical alternative anti-giardial therapeutics sidestepping the obstacles of MTZ like dysplasia and teratogenicity.

## Introduction

*Giardia lamblia* is a very common intestinal protozoan causing diarrhea among children and affects about 200 million people per year; mainly in Africa, Asia and America [1]. Malabsorption, abdominal pain and loss of weight are the main

complaints leading to delayed growth and development with mild self-limiting illness or a several months-chronic illness [2].

Microscopy using wet mount or iodine stain is the gold standard methodology for *G. lamblia*

diagnosis [3]. However, false-negative results due to intermittence and low number of the cysts shed in fecal samples may be encountered. To overcome these obstacles, a combination of diagnostic methods is frequently indicated [4]. In the past years, several complementary, immunological diagnostic methods for giardiasis have been encountered. Immunochromatographic devices are promising tools in the diagnosis being reliable in identifying the positive and negative stool samples. Superiority of immunochromatographic method over conventional microscopy is linked to its capability of detection of minimal quantities of antigens, even with low burden of the parasite, wherever several fecal samples are required by conventional microscopy, especially with the intermittent cyst shedding in chronic infections [5], or damaged cysts with frozen fecal samples [6].

Commercial anti-giardial drugs include nitroimidazoles e.g. metronidazole (MTZ); benzimidazoles, e.g. fenbendazole; and paromomycin [7]. However, most of these chemotherapeutics may cause severe side effects and are not well tolerated by human and animals [8]. Moreover, clinical failure and drug resistance were also detected [9]. Hence, many studies tried to identify new natural anti-giardial alternatives [10]. In traditional medicine, olibanum (OL) or frankincense; a natural *oleogum* resin from *Boswellia* species, is often used for the treatment of variety of diseases. Animal experiments showed evidence based anti-inflammatory activity of OL [11]. The immunostimulant, immunomodulatory, and anti-leukotriene activities are added values to its use in several immune disorders [12]. Abdalla et al. [13] have defined the antiparasitic activity of OL in vivo and using in-vitro culture of *G. lamblia* trophozoites on TYI-S-33 medium. Propolis (PR) extracts have antiseptic, anti-inflammatory, antioxidant, and anticancer activities. Moreover, antimicrobial besides antiulcer and immunomodulatory properties could be detected [14]. Propolis was promisingly proposed to manage giardiasis with minimal side effects [15].

This study was conducted to assess the therapeutic efficacy of OL, PR, and their combination versus MTZ as non-chemical therapeutic alternatives for control of *G. lamblia* infection in experimentally infected mice.

## Material and Methods

### Parasites purification

Fresh stool samples containing at least five *G. lamblia* cysts by high power field in a routine saline smear and free from other parasites, were obtained

from 3 heavily infected patients attending the Outpatient Clinic of the Pediatric Department of Zagazig University Hospital. Emulsification of the samples in saline and sieving were done to remove the large particles. The cysts were concentrated by repeated centrifugation (2000 r.p.m for 5 min.) and washing in saline. After the last washing, the deposit was mixed thoroughly with normal saline and the number of cysts in the suspension was adjusted by the haemocytometer to be 500,000 cysts/ml [16].

### Herbal preparation and extraction

Olibanum was purchased from Egyptian market as solid whitish masses. Chemical identification was carried out according to Abdallah et al. [13]. Ten grams were extracted with 50 ml absolute ethanol. The combined ethanol extracts were filtered and evaporation using a rotator evaporator and freeze dryer. Ethanol (70%) was added to the dried extract to obtain a concentration of 200 µg /ml solvent. Propolis (Biopropolis) tablets 400mg [Sigma, Egypt]: The drug was given orally in the form of aqueous suspension in a single daily dose of 1.04 mg/0.2ml/mouse (Paget and Barnes, 1964). Chemotherapy: Metronidazole (Flagyl) tablets 500mg [EPICO, Egypt]: The drug was given orally in the form of aqueous suspension in a daily dose 1.37 mg/0.2ml/mouse [17].

This experimental study was carried out at Medical Parasitology Department, Faculty of Medicine, Zagazig University and Theodor Bilharz research institute (TBRI), on 60 apparently healthy laboratory bred male Swiss albino mice, with a weight range of 20-25grams, aged six to eight weeks old. Mice were kept in numbered clean cages, maintained on stock diet and kept under fixed appropriate conditions of housing and handling in animal house of TBRI. Every day, food and water containers, wire inserts were thoroughly washed by hot water. All mice were maintained according to the research protocols following the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals, and as approved by ethics committee of TBRI. Mice were treated for three consecutive days with metronidazole solution (10 mg/mouse/day), which was administered orally. One week after treatment, three consecutive fecal examinations were performed prior to experimental infections. This treatment ensured that mice were free from all possible protozoan infections.

Out of the current prepared suspension, containing 500,000 *G. lamblia* cysts, one inoculum of 100,000 cysts/0.2ml/mouse was aspirated in a tuberculin

syringe to which a blunt tipped needle was applied. The mouse was held by the left hand slightly bent backwards. The curved needle was gently and carefully introduced into the pharyngeal opening and the inoculum dose was slowly administered into the stomach [16]. Successive stool samples from each mouse were collected in a dry labeled, wide-mouth plastic container with tight fitting cover to be immediately examined by iodine-stained smears either directly or by concentration method. To confirm the induction of infection, stool samples from animals were checked daily for the presence of *G. lamblia* cysts by iodine-stained smears.

Treatment with the two medicinal extracts and metronidazole was started on the 6<sup>th</sup> day post-infection (dPI); [peak of intestinal colonization], for seven consecutive days. Mice were randomly divided into six groups (10 mice each): GI (Control normal): Normal control (non-treated and non-infected mice). GII (Control infected): Infected without receiving any treatment. GIII (OL): Infected and treated intragastrically with 25µl of the olibanum extract, dissolved in 70% ethanol, was given in a single daily dose. Its chemical identification was performed by Mikhaeil et al. [12]. GIV (PR): Mice infected and treated with 1.04 mg/0.2ml/mouse, was given in a single daily dose. GV (Combination of OL&PR): Full doses of both olibanum and propolis extracts, were given in a single daily dose [18]. GVI (MTZ): Metronidazole was given orally in the form of aqueous suspension in a single daily dose (1.37 mg/0.2ml/mouse) [17].

Parasitological assay: Mice were sacrificed, and intestinal washes were examined on the following different (8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI). The proximal 1 cm segment of each mouse jejunum was removed, placed in 1 ml of chilled sterile Phosphate buffered (PBS) saline, and after 15 minutes on ice was vortexed for 30 seconds to release trophozoites from intestinal wall. Trophozoites were counted on a haemocytometer; at least four separate quadrants (grids) on the haemocytometer were counted for each mouse since a single parasite on one grid corresponds to  $\times 10^4$ /ml [19]. The percentage reduction (%R) in the parasite count was calculated according to the following equation: %R= 100 (C-E)/C, where C: infected control group and E: Experimental groups of mice [20].

Detection of *G. lamblia* antigen in stool samples of the mice on the 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI was done by a quick immunochromatographic test using commercially available RIDA-Quick (R-

BiopharmGmb H, Darmstadt, Germany) kit. The method was done according to manufacturer's instructions. Stool samples were considered positive if *red* and *blue* bands were seen in the strips and were considered negative if only the *blue* band was visible in the test strips. The test is considered invalid if no bands appear or a combination other than the one described above or other changes in band colour. Likewise, changes in band colour which appear after 10 minutes or later are also without any diagnostic value and must not be used for evaluation [21].

Histopathological examination: Duodenal and jejunal specimens of sacrificed mice, on the 12<sup>th</sup> and 15<sup>th</sup> dPI, were fixed in 10% formalin and kept as paraffin blocks. Microtome sections were cut at a thickness of 4 µm, stained with (H&E), then experienced histopathological examination to assess the histopathological changes that occurred during the infection and detect the degree of affection of mucosa after treatment [22].

Data are presented as mean and standard deviations ( $\pm$  SD). Statistical significance was determined by two-way ANOVA, followed by a post hoc Bonferroni test, one-way ANOVA with Tukey's Multiple Comparison Test, unpaired Student's t-test for selected pairs of data using Graph Pad Prism version 5 (Graph Pad Software). *P values* >0.05 are considered non-significant. Significant *p value* <0.05 and highly significant *P value* <0.001.

## Results

In comparison to control infected group (GII), there was a high significant difference among all studied groups (*P*<0.001), and a significant decrease in the mean *Giardia* trophozoite count in all treated groups (*P*<0.05) on the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI. Also, (GIII & GIV) showed significant decrease in trophozoite count [Reference drug] (*P*<0.05), but (GV) showed significant difference (*P*>0.05) on the 8<sup>th</sup> and 12<sup>th</sup> dPI but significantly different (*P*>0.05) on the 15<sup>th</sup> dPI in comparison to (GVI) (**Table 1**). Percentage reduction of trophozoite count in intestinal washes showed that (GIII & GIV) showed significant increase (*P*<0.05) in comparison to GVI on the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI. But, no significant difference (*P*>0.05) in percentage of reduction was found between (GV&GVI) (**Table 2**).

On the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI, all the tested treated groups showed significant decrease in number of positive Immunochromatographic Test (ICT) in comparison to control infected group (*P*<0.05). Also, there was significant difference in

number of positive ICT+ve of GIII&GIV in comparison to GVI ( $P<0.05$ ). On the other hand, no significant difference ( $P>0.05$ ) in ICT +ve test number was found between (GV&GVI) (**Table 3**).

Inflammatory cell infiltrate count, on the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI showed highly significant difference between all the studied groups ( $P<0.001$ ), and a significant decrease in all tested treated groups in comparison to GII ( $P<0.05$ ). Also, (GIII & GIV) showed significant decrease in comparison to (GVI); ( $P<0.05$ ), but (GV) showed no significant difference ( $P>0.05$ ) in comparison to (GVI). Percentage reduction of inflammatory cell infiltrate count showed that (GIII & GIV) showed significant increase ( $P<0.05$ ) in comparison to (GVI) on the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI. But, no significant difference ( $P>0.05$ ) in percentage of reduction was found between (GV&GVI) (**Table 4**).

Comparing the groups to normal intestinal histopathology, GII showed marked changes in the form of marked infiltration of lamina propria with inflammatory cells with fusion of villi, goblet cell depletion and heavy *Giardia* trophozoite infection on the 12<sup>th</sup> and 15<sup>th</sup> dPI (**Figures 3, 4,5**). After treatment,

**Table 1.** Mean counts of *G. lamblia* trophozoites ( $\times 10^4$ /ml) from intestinal washes of infected mice treated with different drugs at different post-infection days (dPI).

Groups	Days Post infection		
	8 <sup>th</sup> dPI	12 <sup>th</sup> dPI	15 <sup>th</sup> dPI
<b>Infected control</b>	32.21±0.45	64.40±0.96	79.12±0.10
<b>Olibanum (OL)</b>	22.21±0.31 <sup>#@</sup>	19.50±0.40 <sup>#@</sup>	13.13±0.13 <sup>#@</sup>
<b>Propolis (PR)</b>	16.65±0.25 <sup>#@</sup>	11.21±0.65 <sup>#@</sup>	6.77±0.10 <sup>#@</sup>
<b>Combined OL &amp; PR</b>	5.64±0.15 <sup>#@</sup>	2.16±0.15 <sup>#@</sup>	00 <sup>#</sup>
<b>MTZ</b>	2.10±0.05 <sup>#</sup>	0.09±0.03 <sup>#</sup>	00 <sup>#</sup>
<b>F</b>	19490	22604	1.530e+006
<b>P</b>	< 0.001	< 0.001	< 0.001

(@) =  $p<0.05$  compared to MTZ group. (#) =  $p<0.05$  compared to infected control group. Data are presented as mean ± SD, and analyzed by 2-way ANOVA, followed by a post hoc Bonferroni test.

histopathological improvement on the 15<sup>th</sup> dPI appeared in sections of the small intestine from mice of (GIII, IV, V&VI) compared to GII. GIII showed mild improvement in the histopathological changes on the 15<sup>th</sup> dPI, as intestinal mucosa showed mild to moderate inflammatory cell infiltrate, normal goblet cells and no *Giardia* trophozoite attached to the villi (**Figures 7, 8**). GIV showed a moderate improvement on the 15<sup>th</sup> dPI in the form of moderate inflammation with no organism in between the villi and normal goblet cells (**Figure 10**). GV showed high degree of improvement on the 15<sup>th</sup> dPI in the form of marked healing of intestinal mucosa with clearance of *Giardia* infection and nearly intact villi (**Figure 12**). GVI showed the highest degree of improvement on the 15<sup>th</sup> dPI in the form of marked healing of intestinal mucosa, preservation of brush border, with clearance of *Giardia* infection and nearly intact villi but with mild cell dysplasia (**Figure 14,15**), and moderate degree of dysplasia with mitotic figures (**Figure 16**).

**Table 2.** Percentage of reduction in *Giardia* trophozoite in intestinal wash among different treated groups on different post-infection days (dPI).

Groups	Percentage of reduction		
	8 <sup>th</sup> dPI	12 <sup>th</sup> dPI	15 <sup>th</sup> dPI
<b>Olibanum</b>	31 @#	70 @#	83 @#
<b>Propolis</b>	48 @#	83 @#	91 @#
<b>Combined OL&amp;PR</b>	82	97	100
<b>MTZ</b>	93	100	100

(@) =  $p < 0.05$  compared to MTZ-group. (#) =  $p < 0.05$  compared to combination group. Data are analyzed by Chi-square test.

**Table 3.** Percentage of Immunochromatography positive mice (ICT +ve) for *Giardia* copro-antigen on different days of assessment.

Study groups	Percentage (%) of ICT +ve mice		
	8 <sup>th</sup> dPI	12 <sup>th</sup> dPI	15 <sup>th</sup> dPI
<b>Infected control</b>	100	100	100
<b>OL</b>	60 @#	40 @#	30 @#
<b>PR</b>	40 @#	30 @#	20 @#
<b>Combined OL&amp;PR</b>	20 #	10 #	0 #
<b>MTZ</b>	10 #	10 #	0 #


(@) =  $p < 0.05$  compared to (MTZ). (#) =  $p < 0.05$  compared to infected control. Data are analyzed by Chi-square test.

**Table 4.** Mean count and percentage reduction (R%) of inflammatory cell count/ H.P.F in duodenum and jejunum of sacrificed mice on the 12<sup>th</sup> and 15<sup>th</sup> days PI stained with hematoxylin and eosin (H&E) stain.


Groups	12 <sup>th</sup> day post infection		15 <sup>th</sup> day post infection	
	inflammatory cell count	R%	R%	inflammatory cell count
<b>Normal control</b>	25.9 ± 3.5			
<b>Infected control</b>	93.9±2.7			102.4 ± 4.25
<b>OL</b>	82.1±4.3 #@	12.57	37.99	63.5 ± 6.2 #@
<b>PR</b>	77.4±3.1 #@	17.57	43.75	57.6 ± 3.6 #@
<b>Combined OL&amp; PRRP</b>	57.8±6.2 #	38.45	74.41	26..2 ± 5.0 #
<b>MTZ</b>	53.4±3.9 #	43.13	72.36	28.3 ± 2.5 #
<b>F</b>	355.0	1.323		551.9
<b>P</b>	< 0.001	0.3838		< 0.001

(@) =  $p < 0.05$  compared to MTZ group. (#) =  $p < 0.05$  compared to infected control group. \*Data are analyzed by 2-way ANOVA, followed by a post hoc Bonferroni test.


**Figure 1.** Jejunal section of non-infected, non-treated control mouse (GI) on the 12<sup>th</sup> dPI showing normal intact villi with normal inflammatory cell infiltrate with normal goblet cell content (X100, H&E). **Figure 2.** Jejunal section of non-infected non-treated control mouse (GI) on the 15<sup>th</sup> dPI showing normal intact villi with normal inflammatory cell infiltrate with normal goblet cell content (X 400, H&E).




**Figure 3.** Jejunal section of an infected non-treated mouse (GII) on the 12<sup>th</sup> dPI showing with goblet cell depletion with heavy giardial infection, Arrow to *Giardia* Trophozoite (X1000 H&E). **Figure 4.** Jejunal section of an infected non-treated mouse (GII) on the 12<sup>th</sup> day PI showing marked infiltration of lamina propria with inflammatory cells with goblet cell depletion with heavy *Giardia* trophozoite infection (X400, H&E). **Figure 5.** Jejunal section of an infected non-treated mouse (GII) on the 15<sup>th</sup> dPI showing marked infiltration of lamina propria with inflammatory cells with fusion of villi and goblet cell depletion with heavy giardial trophozoite infection; arrow (X400, H&E).




**Figure 6.** Jejunal section of an infected olibanum-treated mouse (GIII) on the 12<sup>th</sup> dPI showing moderate infiltration of lamina propria with inflammatory cells with goblet cell depletion and *Giardia* trophozoites in between villi (X400, H&E).



**Figure 7.** Jejunal section of an infected olibanum-treated mouse (GIII) on the 15<sup>th</sup> dPI showing mild infiltration of lamina propria with inflammatory cells, goblet cells begin to be restored, no *Giardia* trophozoites in between villi (X200, H&E). **Figure 8.** Jejunal section of an infected olibanum-treated mouse (GIII) on the 15<sup>th</sup> dPI showing mild infiltration of lamina propria with inflammatory cells, goblet cells begin to be restored, no *Giardia* trophozoites in between villi (X400, H&E).




**Figure 9.** Jejunal section of an infected propolis-treated mouse (GIV) on the 12<sup>th</sup> day PI showing mild to moderate infiltration of lamina propria with inflammatory cells with goblet cell depletion with *Giardia* trophozoites in between villi (X400, H&E).




**Figure 10.** Jejunal section of an infected propolis-treated mouse (GIV) on the 15<sup>th</sup> dPI showing mild infiltration of lamina propria with inflammatory cells with goblet cells begin to be restored, no *Giardia* trophozoites in between villi (X400, H&E).

**Figure 11.** Jejunal section of an infected combination-treated mouse (GV) on the 12<sup>th</sup> dPI showing mild infiltration of lamina propria with inflammatory cells with goblet cell depletion with *Giardia* trophozoites in between villi (X400, H&E).







**Figure 12.** Jejunal section of an infected combination-treated mouse (GV) on the 15<sup>th</sup> dPI showing normal infiltration of lamina propria with inflammatory cells with goblet cells restored to be normal, no *Giardia* trophozoites in between villi (X400, H&E). **Figure 13.** Jejunal section of an infected MTZ-treated mouse (GVI) on the 12<sup>th</sup> day PI showing mild infiltration of lamina propria with inflammatory cells with goblet cell depletion and *Giardia* trophozoites in between villi (X400, H&E).



**Figure 14.** Jejunal section of an infected MTZ-treated mouse (GVI) on the 15<sup>th</sup> dPI showing mild cell dysplasia, normal infiltration of lamina propria with inflammatory cells with goblet cells restored to be normal, no *Giardia* trophozoites in between villi (X400, H&E). **Figure 15.** Jejunal section of an infected MTZ-treated mouse (GVI) on the 12<sup>th</sup> dPI revealing mild cell dysplasia, (X1000, H&E).



**Figure 16.** Jejunal section of an infected MTZ-treated mouse (GVI) on the 15<sup>th</sup> dPI revealing moderate cell dysplasia with mitotic figures, (X1000, H&E).



## Discussion

*Giardia lamblia* is a flagellated protozoan parasite inhabiting the small intestine. It contributes to global waterborne outbreaks of acute and persistent fatty diarrhea of all ages. Additionally, it may be complicated with sugars and fats malabsorption, chloride hypersecretion and increased intestinal transit [23]. Chemotherapeutics

like MTZ, as a first-line treatment, nitroimidazoles, benzimidazoles, and their derivatives have been also used for giardiasis [24]. Despite their efficacy; relapses and proved carcinogenicity in experimental animals are still obstacles in use [25]. Dangerous adverse reactions e.g. leukopenia and neurotoxic effects as ataxia, seizures and vertigo, sometimes lead to chemotherapeutic discontinuation [26]. Treatment failures may also occur Thus longer repeated courses, higher doses, or even changing drug-class could be helpful to avoid the potential cross-resistance. In this context, combination therapy (CT) is emerging as a valuable option against refractory giardiasis [27], but increased parasite resistance to such drugs rendered urgent identification of novel, effective, non-chemical and safe agents for control of giardiasis [10].

With the hope of shedding some light on the natural alternative medicine in treatment of giardiasis, the present work was designed to study the effect of OL (*Boswellia serrate*), and PR (Biopropolis tablets) on experimental *Giardia* infection and their combined effect versus metronidazole therapy.

Olibanum or frankincense, the natural oleo-gum-resin, is a term to describe oleo (oily in nature) gum (partly soluble in water) resin (partly or wholly soluble in alcohol) [12]. It comprises an acid resin (Boswellic acid) (56-60%), gum (30-36%), and volatile oil (3-8%). Ether soluble resin can be extracted from OL-gum [28]. **Borrelli et al.** [29] observed the OL-predominant anti-inflammatory activity to alleviate the gut functional troubles by improving motility, inhibiting diarrhea without constipation, inhibiting contraction of intestinal smooth muscles and control acetylcholine and barium chloride induced diarrhea [30]. So, OL showed an evidence in ulcerative colitis [31], Crohn's disease [32], and collagenous colitis [33]. *Boswellia's* antioxidant activity is the mechanism involved in the physiologic maintenance of the integrity and function of the enterocytes [34], where the epithelial barrier is involved in *Giardia* infection [35] and OL presents benefits in this track [36].

Propolis was promisingly proposed to manage giardiasis as a natural source with the benefit of minimal level of side effects. Its crucial anti-giardial efficacy could be endorsed by the antioxidant effect of flavonoids concentrated in PR [37], or immunomodulatory properties via augmenting nonspecific host defense mechanisms after macrophage activation [38, 39]. Also, **Soufy et**

al. [40] showed the benefits of ethanolic and water extracts of Egyptian PR at a dose of 50 mg/kg against immunosuppressed *Cryptosporidium* infected rats, resulting in significant reduction of oocysts count in stool. The maximal reduction reached 89% on the 7<sup>th</sup> dPI. Its antiparasitic effect may be attributed to its phenolic compounds, which could enhance the oxidative defense mechanisms [41] or stimulate the immune system [42] leading to increased antibody titers with the reduction of oocysts shedding [43].

In the current study, OL treated group showed significant decrease in mean count of *Giardia* trophozoites in intestinal wash in comparison to control infected group. Similar results were obtained by **Abdallah et al.** [13] who found that OL of 10, 15, and 20 mg/kg/day inhibited *G. lamblia* multiplication *in vivo* in a dose-dependent manner. It improved the histopathological changes caused by infection in the duodenum and jejunum. These results confirm the antiparasitic effects of these medicinal herbs on *G. lamblia*, as a promising alternative to MTZ. Moreover, all treated groups showed highly significant decline in *G. lamblia* trophozoites from intestinal washes of infected mice treated with different drugs in comparison to GII with successive improvement in trophozoite reduction on the 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI, after completing all therapeutic doses of all regimens. Similar results were reported by **Abd El Fattah and Nada** [44] who found PR gave a highly significant decrease in *Giardia* trophozoite count than that obtained by MTZ on the 6<sup>th</sup> dPI, but the efficacy was almost equal to that detected on the 12<sup>th</sup> dPI. However, **Freitas et al.** [45] stated that Brazilian PR triggered inhibition of *Giardia* trophozoites growth *in vitro*, the level of which varied according to its concentration and incubation times. The lowest concentrations of PR (7.81 and 15.63 mg/ml) failed to affect parasites growth, while higher ones (31.25 mg/ml) showed an effect and the highest giardial growth reduction was in cultures exposed to 125, 250 and 500 mg/ml of extract at all incubation periods, with the highest reduction of trophozoite adherence to 67.9% and 69.5% of 250 and 500 mg/ml concentrations respectively, while MTZ reduced trophozoite adherence to 100%. These findings agreed with **Thabet and Abdel-Fattah** [46] who studied the inhibitory effect of Egyptian PR extract on *G. lamblia* trophozoite *in vitro*, where 250 µg/ml concentration of it showed growth reduction by (90.7%); after 72h, while on increasing

its dose, reached 100% compared to (83.3%) reduction obtained by MTZ, while its inhibitory effect on parasite adherence was the same as that obtained by MTZ. They also showed that PR in a dose 500µg/ml exerted 100% adherence reduction after 72h.

The previous results were confirmed by Immunochromatographic Test (ICT) which revealed that all treated groups showed significant decrease in number of positive ICT on the entire 8<sup>th</sup>, 12<sup>th</sup> and 15<sup>th</sup> dPI in comparison to control infected group. On the other hand, no significant difference found between the tested natural therapeutic medicine (GIII&GIV) in comparison to each other and in comparison, with MTZ. While (PR & OL) combination produced results close to MTZ with the benefits of minimal level of side effects during treatment.

Experimental giardiasis eventually creates a physical barrier between the enterocytes and the lumen, villus atrophy, crypt hyperplasia, further interfering with nutrient absorption, intestinal hyperpermeability, and brush border damage [47], goblet cell depletion and shortening of the microvilli [48] with the resultant diminished absorptive surface area [49]. In the present study, non-chemical therapeutic trials by OL and PR for giardiasis resulted in enhanced brush border surface area. On the 12<sup>th</sup> dPI, GIV revealed destruction of the villi due to desquamation, sloughing of epithelial cells and complete cell necrosis. Broadening, fusion and flattening to tips of villi, crypt hyperplasia with abnormal villous/crypt ratio were also noticed with inflammatory cell infiltrate within the lamina propria. However, on the 15<sup>th</sup> dPI, improvement in villous architecture was noticed with clearance of *Giardia* trophozoites. This was in accordance with **Buret** [50], who detected also increased intestinal disaccharidase activity and decreased intraepithelial lymphocytes. **Buret** [51] also added that shortening of the microvilli could aggravate the deficiency in enzymatic and absorptive capability of enterocytes. However, **Chin et al.** [47] detected apoptotic changes of enterocytes in giardiasis infection. Close results were reported by **Abdel-Fattah and Nada** [44] who reported that combined use of MTZ and PR caused an immunological balance that saved normal architecture of villi. In this study, GVI; on the 12<sup>th</sup> dPI showed mild shortening, blunting and fusion of the villi with focal cellular infiltration within the lamina propria. Then, on the 15<sup>th</sup> dPI, there was pronounced improvement of mucosal



changes with normal villous architecture, with increasing degrees of dysplastic changes and mitotic figures. Close reports were recorded by **Eissa and Amer** [52] described MTZ treated mice with lamina propria mild inflammatory infiltrate, focal shortening of the villi and the presence with few *G. lamblia* trophozoites. Moreover, **Ammar et al.** [53] observed partial healing of the intestinal mucosa and villous crypts ratio of *Giardia* infected hamsters treated with MTZ.

Collectively, combination of propolis and olibanum gave better results than using them individually and near-by results to MTZ, confirmed by the used parameters. These results may be attributed to the augmented anti-inflammatory, antioxidant and immune-stimulant effects of both of them. Furthermore, their combination may be involved in the physiologic maintenance of the integrity and function of the intestinal epithelium. This enhances the use of non-chemical safe alternatives as anti-giardial agents, mainly for pediatrics and pregnant.

**Declaration of interest:** The authors confirm that there is no conflict of interest.

**Financial disclosure:** none declared

## References

- 1-Manko A, Motta JP, Cotton JA, Feener T, Oyeyemi A, Vallance BA, et al. *Giardia* co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease. *PLoS ONE* 2017; 12: e0178647.
- 2-Allain T, Amat CB, Motta JP, Manko A, Buret AG. Interactions of *Giardia* sp. with the intestinal barrier: Epithelium, mucus, and microbiota. *Tissue Barriers* 2017; 5(1): e1274354.
- 3-Payne P, Artzer M. The biology and control of *Giardia* spp. and *Trichomonas foetus*. *Vet Clin N Am Small* 2009; 39(6): 993-1007.
- 4-Tangtrongsup S, Scorza V. Update on the diagnosis and management of *Giardia* spp. infections in dogs and cats. *Topics in Companion Animal Medicine* 2010; 25(3): 155-162.
- 5-Mahdy AkM, Yal L, Surin J, Wan Kl, Al-Mekhlafi Msh. Risk factors for endemic giardiasis: highlighting the possible association of contaminated water and food. *Trans R Soc Trop Med Hygiene* 2008; 102: 465-470.
- 6-Costa VA, Brener B, Fonseca ABM, Sudre, AP. Modification of the Alere *Giardia*-Ag Test Immunochromatography Kit methodology for its use in frozen fecal sediment of dogs and cats. *Anais da Academia Brasileira de Ciências* 2018; 90(1): 479-483.
- 7-Minetti C, Chalmers RM, Beeching NJ, Probert C, Lamden K. Giardiasis. *BMJ* 2016; 355: i5369.
- 8-Amer EI, Mossallam SF, Mahrous H. Therapeutic enhancement of newly derived bacteriocins against *Giardia lamblia*. *Exp. Parasitol* 2014; 146: 52–63.
- 9-Hart CJS, Munro T, Andrews KT, Ryan JH, Riches AG, Skinner-Adams TS. A novel in vitro image-based assay identifies new drug leads for giardiasis. *Int J Parasitol: Drugs and Drug Resist* 2017; 7: 83–89.
- 10-Sanad M, Abo El Maaty D, Abd El-Aal N, Al-Ghandour AMF, Farag A, Yousef A, et al. Therapeutic Efficacy of Probiotics Against Experimental Giardiasis: Histopathological, Histochemical and Ultrastructural Changes. *Journal of The Egyptian Society of Parasitology* 2020; 50(1): 21-32.
- 11-Ammon HP. Boswellic acids in chronic inflammatory diseases. *Planta Med* 2006; 72(12): 1100-16.
- 12-Mikhaeil BR, Maatooq GT, Badria FA, Amer MM. Chemistry and immunomodulatory activity of frankincense oil. *Z Naturforsch* 2003; 58(3-4):230-8.

- 13-Abdalla SF, Ramadan NI, Mohamed AA, El-Deeb HK, Al-Khadrawy FM, Badawy AF.** A study on the effect of *Myrtus communis* and *Olibanum* on *Giardia lamblia* infection in Egypt. P U J 2011; 4(1):89-100.
- 14-Pasupuleti VR, Sammugam L, Ramesh N, Gan SH.** Honey, propolis, and royal jelly: a comprehensive review of their biological actions and health benefits. Oxidative medicine and cellular longevity 2017; 2017
- 15-Paulino N, Coutinho LA, Coutinho JR, Vilela GC, da Silva Leandro VP, Paulino A. S.** Antiulcerogenic effect of Brazilian propolis formulation in mice. Pharmacology & Pharmacy 2015; 6(12): 580.
- 16-Hill DR, Guerrant RL, Pearson RD.** *Giardia lamblia* infection of suckling mice. J Infect Dis 1983; 147: 217-21.
- 17-Paget GE, Barnes JM.** Interspecies dosage conversion scheme in evaluation of results and quantitative application in different species. Evaluation of drug activities: pharmacometrics 1964; 1: 160-162.
- 18-Barbosa E, Calzada F, Campos R** Antigiardial activity of methanolic extracts from *Helianthemum glomeratum* Lag. and *Rubus coriifolius* Focke in suckling mice CD-1. J Ethnopharmacol 2006; 108(3): 395-7.
- 19-Singer SM, Nash TE.** T-cell dependent control of acute *Giardia lamblia* infection in mice. J Infect Dis 2000; 181:1510-1512.
- 20-Penido MLO, Nelson DL, Vieira LQ, Coelho PMZ.** Schistosomal activity of alkyl amino-octanethiosulfuric acids. Mem. Inst. Oswaldo Cruz 1994; 89(4): 595-602.
- 21-Koivunen ME, Krogsrud RL** Principles of Immunochemical Techniques Used in Clinical Laboratories. Lab Medicine 2006; (8): 490 - 497.
- 22-Slaoui M, Fiette L.** Histopathology Procedures: From Tissue Sampling to Histopathological Evaluation. In: Gautier, J.C. (eds) Drug Safety Evaluation, Methods in Molecular Biology (Methods and Protocols). Vol. 691. Humana Press Inc, Totowa, New Jersey, USA; 2011
- 23-Torgerson PR, Devleeschauwer B, Praet N, Speybroeck N, Willingham AL, Kasuga F, et al.** World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. PLOS Medicine 2015; 12(12): e1001920.
- 24-Campanati L, Monteiro-Leal LH.** The effects of the antiprotozoal drugs metronidazole and furazolidone on trophozoites of *Giardia lamblia* (P1 strain). Parasitology Research 2002; 88: 80-85.
- 25-Cohen SM, Lower GM, Erturk E, Bryan GT.** Comparative Carcinogenicity in Swiss Mice of A<sup>+</sup>[4-(5-Nitro-2-furyl)-2-thiazolyl] acetamide and Structurally Related 5-Nitrofurans and 4-Nitrobenzenes. Cancer research 1973; 33: 1593-1597.
- 26-Andrade EC, Leite ICG, Rodrigues VO, Cesca MG.** Parasitoses intestinais: uma revisão sobre seus aspectos sociais, epidemiológicos, clínicos e terapêuticos. Rev. APS 2010; 13: 231-240.
- 27-Escobedo A, Lalle M, Hrastnik N, Rodriguez-Morales AJ, Castro Sanchez EM, Cimerman S, et al.** Combination therapy in the management of giardiasis: What laboratory and clinical studies tell us, so far. Acta Trop 2016; 162:196-205.
- 28-Chowdary KPR, Mohapatra P, Murali Krishna MN.** Evaluation of Olibanum resin as a microencapsulating agent for controlled drug

- delivery. Indian J Pharm Sci 2006; 68(4): 461-464.
- 29-Borrelli F, Capasso F, Capasso R, Ascione V, Aviello G, Longo R.** Effect of *Boswellia serrata* on Intestinal Motility in Rodents: Inhibition of Diarrhoea without Constipation. British Journal of Pharmacology 2006; 148: 553–560
- 30-Carroccio A, Cavataio F, Montalto G, Paparo F, Troncone R, Iacono G.** Treatment of giardiasis reverses ‘active’ coeliac disease to ‘latent’ coeliac disease. European journal of gastroenterology & hepatology 2001; 13(9): 1101-1105.
- 31-Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D.** Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS J 2006; 273: 5320-5332
- 32-Gerhardt H, Seifert F, Buvari P, Vogel-Sang H, Reppes R.** Therapy of active crohn diseases with *Boswellia serrata* extract H 15, Gastroentrol 2001; 39: 11-17.
- 33-Madisch A, Miehle S, Eichele O, Mrwa J, Bethke B.** *Boswellia serrata* extract for the treatment of collagenous colitis, A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007; 22: 1445-1451.
- 34-Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, Giron MC, et al.** *Boswellia serrata* Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. PLoS ONE 2015; 10(5): e0125375.
- 35-Dagci H, Ustun S, Taner MS, Ersoz G, Karacasu F, Budak S.** Protozoan infections and intestinal permeability. Acta Trop 2002; 81: 1-5.
- 36-Khan I, Samson SE, Grover AK.** “Antioxidant Supplements and Gastrointestinal Diseases: A Critical Appraisal”. Med Princ Pract 2017; 26: 201–217
- 37-Usman UZ, Abu Bakar AB, Mohamed M.** Phytochemical screening and comparison of antioxidant activity of water and ethanol extract propolis from Malaysia. International Journal of Pharmacy and Pharmaceutical Sciences 2016; 8(5): 413–415.
- 38- Sayed SM, Abou El-Ella GA, Wahba NM, El Nisr NA, Raddad K, Abd El Rahman MF, et al.** Immune Defense of Rats Immunized with Fennel Honey, Propolis, and Bee Venom Against Induced Staphylococcal Infection Journal of Medicinal Food 2009; 12(3): 569-75.
- 39-Dimov V, Ivanovska NN, Manolova N Bankova, V, Nikolov N, Popov S** Immunomodulatory action of propolis. Influence on anti-infections protection and macrophage function. Apidologie 1991; 22 (2): 155-162
- 40-Soufy H, El-Beih NM, Nasr SM, Abd El-Aziz TH, Khalil FAM, Ahmed YF , et al.** Effect of Egyptian propolis on cryptosporidiosis in immunosuppressed rats with special emphasis on oocysts shedding, leukogram, protein profile and ileum histopathology. Asian Pac J Trop Med 2017; 10(3): 253-262.
- 41-Zeedan GSG, Allam AMM, Nasr SM, Abd alhamed AM.** Evaluation the efficacy of Egyptian propolis against parapox viruses by production of IFN- $\gamma$ , TNF- $\alpha$  and immunoglobulin in experimental rat. World Appl Sci J 2014; 31(2): 199-207.
- 42-Zenner L, Callait MP, Granier C, Chauve C.** In vitro effect of essential oils from *Cinnamomum aromaticum*, *Citrus limon* and *Allium sativum* on two intestinal flagellates of poultry, *Tetratrichomonas*

- gallinarum and *Histomonas meleagridis*. Parasite 2003; 10: 153-157.
- 43-Martín-Gómez S, Álvarez-Sánchez M, Rojo-Vázquez F.** A newborn mouse *Cryptosporidium parvum* infection model: its application to the study of therapeutic and prophylactic measures for controlling cryptosporidiosis in ruminants. Parasitol Res 2006;99 (1): 1-6.
- 44-Abdel-Fattah NS, Nada OH.** Effect of propolis versus metronidazole and their combined use in treatment of acute experimental giardiasis. J. Egypt Soc Parasitol 2007; 37(2): 691-710.
- 45-Freitas SF, Shinohara L, Sforcin JM, Guimarães S.** In vitro effects of propolis on *Giardia duodenalis* trophozoites. phymed. 2004.07.008. Epub 2005; 13(3): 170-5.
- 46-Thabet HS, Abdel-Fattah NS.** In vitro effect of propolis versus wheat germ agglutinin on growth and adherence of an Egyptian *Giardia lamblia* trophozoite strain. New Egypt J Med 2006; 35(1): 30-37.
- 47-Chin AC, Teoh DA, Scott KG, Meddings JB, Macnaughton WK, Buret AG.** Strain-dependent induction of enterocyte apoptosis by *Giardia lamblia* disrupts epithelial barrier function in a caspase-3-dependent manner. Infect Immun 2002; 70: 3673-3680.
- 48-Andersen MD, Neumann NF.** *Giardia intestinalis*: new insights on an old pathogen. Reviews in Medical Microbiology 2007; 18(2): 35-42.
- 49-Buret AG, Mitchell K, Muench DG, Scott KG.** *Giardia lamblia* disrupts tight junctional ZO-1 and increases permeability in non-transformed human small intestinal epithelial monolayers: effects of epidermal growth factor. Parasitology 2002; 125: 11-19.
- 50-Buret AG.** Immunopathology of giardiasis: the role of lymphocytes in intestinal epithelial injury and malfunction AG. Mem Inst Oswaldo Cruz 2005; 100: 185-190.
- 51-Buret AG.** Mechanisms of epithelial dysfunction in giardiasis. Gut 2007; 56: 316-317.
- 52-Eissa MM, Amer EI.** *Giardia lamblia*: A new target for miltefosine. Int J Parasitology 2012; 42(5): 443 - 52.
- 53-Ammar AIA, Mahmoud SSM, El Hefnawy NN.** Effect of ginger on hamsters infected by *Giardia lamblia*. Journal of Environmental Studies and Researches 2014; 1(1): 45-56.